By Timofey Sovershaev, PhD student at TREC
Thrombotic complications are a serious risk in several disorders, including atrial fibrillation, venous thromboembolism and many others. Traditionally, vitamin K antagonists (warfarin) or low-molecular weight heparins were used to prevent such complications. During the last years, a novel drug class, factor Xa inhibitors, has been incorporated into clinical practice, as these drugs have the potential to be safer and easier to use than the traditional vitamin K inhibitors. However, until recently, there was no agent to reverse their effects. Continue reading
